Olsalazine (H.sub.4olz), a prodrug of the anti-inflammatory 5-aminosalicylic acid, is used as a ligand to synthesize a suite of M(H.sub.2olz) and M.sub.2(olz) materials, where M is a dication (e.g. Mg, Ca, Sr, Fe, Co, Ni, Cu, Zn). A family of metal olsalazine coordination polymers, coordination solids, and metal organic frameworks are described, which include 1-, 2-, and 3-dimensional structures. The materials resist degradation at acidic pH and release olsalazine preferentially at neutral pH. The mesoporous M.sub.2(olz) frameworks exhibit high surface areas with hexagonal pore apertures that are approximately 27 in diameter and contain coordinatively unsaturated metal sites. Biologically active molecules containing a Lewis-basic functional group can be grafted directly to the open metal sites of the frameworks. Dissolution of the frameworks under physiological conditions releases olsalazine (H.sub.4olz) and the grafted molecules so that multiple therapeutic components can be delivered together at different rates.

The present invention relates to pharmaceutical composition for the oral delivery of Pentosan Polysulfate sodium (PPS). In particular, the invention discloses compositions of PPS in form of nanoparticles with a suitable polymer aimed to improve the PPS absorption in the small intestine and reduce or eliminate the side effects in the colon.

The present disclosure provides a process of producing a dry powder coated solid, oral administered pharmaceutical osmotic drug delivery system. The method includes preparing a dry powder film forming polymer coating composition to be coated onto an outer surface of the cores, a size of the coating powder being in a range from about 1 nm to about 500 m. The osmotic drug delivery cores are placed into an interior of a rotatable housing and the cores may be preheated. The dry powder coating composition is sprayed into the interior of the housing while the housing is rotating to produce a uniform coating of the dry powder coating composition on the outer surface of the cores. The coated cores are cured form a substantially uniform cured film after which one or more orifices are produced through the uniform cured film to expose the outer surface of the cores at a position of each of the one or more orifices.

The present disclosure provides a process of producing a dry powder coated pharmaceutical capsule. The method includes preparing a dry powder film forming polymer coating composition to be coated onto an outer surface of the capsules, a size of the particulate coating powder being in a range from about 1 nm to about 500 m. The capsules are placed into an interior of a rotatable housing and may be preheated. The dry powder coating composition is sprayed into the interior of the housing while the rotatable housing is rotating to produce a uniform coating of the dry powder coating composition on the outer surface of the capsules. The coated capsules are cured form a substantially uniform cured.

A system for delivering a therapeutic dose of a drug is disclosed. The system includes a delivery medium with therapeutic units attached thereto. The delivery medium is preferably a polymeric hydrogel matrix that has therapeutic units incorporated therein or metal nanoparticles with therapeutic units complexed thereto. The therapeutic units include nucleic acid moieties. The nucleic acid moieties preferably include strands of nucleic acid and drug moieties complexed with the strands of nucleic acid. Where the system includes a polymeric hydrogel matrix, an active drug is controllably released from the polymer hydrogel matrix to provide a therapeutic dose to a biological system or biological tissue. The active drug is controllably released from the hydrogel matrix by altering the environment the hydrogel matrix, or by enzymatic cleavage of the nucleic acid moieties or by a combination thereof.

The present disclosure belongs to the technical field of lipid nanoparticle biological application, and discloses a composite lipid nanoparticle and a preparation method thereof, an ribose nucleic acid (RNA) vaccine, a drug and use. The composite lipid nanoparticle provided by the present disclosure includes a lipid composition and a recombinant antibody protein containing a streptavidin tag; and the lipid composition comprises an ionizable lipid, an auxiliary lipid, cholesterol, a polyethylene glycol lipid and a biotinylated polyethylene glycol lipid in a mass ratio of (40-90):(0.1-20):(20-50):(0.5-10):(0.5-10). Through strong interaction between the recombinant antibody protein with the streptavidin tag and the biotinylated polyethylene glycol lipid in the composite lipid nanoparticle, the composite lipid nanoparticle achieves safe, convenient, rapid, efficient, and stable linkage between a lipid nanoparticle (LNP) and a recombinant antibody protein, and the recombinant antibody protein can be adaptively replaced according to target cells and/or tissues, with high flexibility and applicability.